AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax - LARVOL DELTA

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial (ASH 2025) - P2 | "Reactive capillaryendothelial proliferation, a known camrelizumab-related AE, occurred in 11 patients, all of which weregrade 1.ConclusionCamrelizumab combined with rituximab demonstrated promising efficacy in primary extranodal DLBCL.Sequential R-CHOP therapy further improved the CR rate, with a favorable safety profile. These resultssupport further validation of PD-1-based strategy in frontline management of extranodal DLBCL inprospective randomized studies."

Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • PD-L1

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (clinicaltrials.gov) - P3 | N=423 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatocellular Cancer • Oncology • Solid Tumor

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors. (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Li Min

Checkpoint inhibition • New P2 trial • Oncology • Solid Tumor

Neoadjuvant chemo-immunotherapy with camrelizumab plus chemotherapy in resectable or potentially resectable locally advanced head and neck squamous cell carcinoma: an open-label, single-arm, phase II trial (ESMO Asia 2025) - P2 | "Enrolled patients received camrelizumab (200 mg, iv, q3w) in combination with albumin-paclitaxel (260 mg/m2, iv, q3w) and platinum (cisplatin 75 mg/m2 or carboplatin AUC 5, iv, q3w) for 2 cycles. Neoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed potential efficacy and an acceptable safety profile. This encouraging result promotes us to continue this phase Ⅱ study."

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Survival benefits of immune checkpoint inhibitor plus chemotherapy as first-line treatment for squamous non-small cell lung cancer in the Chinese national medical insurance list: A Bayesian network meta-analysis (ESMO Asia 2025) - "Considering the PFS and OS benefits of camrelizumab plus chemotherapy as first-line treatment for sqNSCLC, it may be regarded as a preferred therapeutic option."

Checkpoint inhibition • Reimbursement • Retrospective data • US reimbursement • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Thalidomide for prevention of camrelizumab-induced RCCEP in advanced NSCLC: A multicenter real-world study (ESMO Asia 2025) - P4 | "Prophylactic thalidomide was associated with a reduced overall incidence and severity of RCCEP in patients receiving camrelizumab-based therapy for advanced NSCLC, with a favorable safety profile. These findings support its potential utility in routine clinical practice to improve treatment tolerability."

Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced oesophageal squamous cell carcinoma: 3-year follow-up from the phase II trial (ESMO Asia 2025) - P=N/A | "Here we report results with 3-year follow-up. Eligible patients with clinical stage T2-4aN0M0, T1-4aN+M0 OSCC were screened and enrolled, treated with regimen of docetaxel (75mg/m2, days 1), carboplatin (AUC=5-6, day 1), camrelizumab (200 mg, day 1) of two 21-day cycles and underwent surgery within 4–6 weeks after neoadjuvant therapy. After a median follow-up of 3-year, neoadjuvant camrelizumab plus chemotherapy continued to demonstrate clinically meaningful improvements in DFS and OS among patients with locally advanced OSCC. ypN0 is associated with lower recurrence. Long-term results from randomized controlled trials are needed."

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Oral Cancer • Squamous Cell Carcinoma

Comparative pathologic complete response of neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors in locally advanced gastric or gastroesophageal junction adenocarcinoma: A systematic review and Bayesian network meta-analysis (ESMO Asia 2025) - "Moderate effects were seen with Camrelizumab + NCT (OR 4.65, CrI: 1.72–13.2; SUCRA 56.94) and Durvalumab + NCT (OR 3.09, CrI: 0.688–13.9; SUCRA 40.12). Atezolizumab + NCT (OR 2.20, CrI: 0.739–8.27; SUCRA 28.04) and Toripalimab + NCT (OR 3.23, CrI: 0.563–20.3; SUCRA 43.21) showed lower efficacy. The addition of PD-1/PD-L1 inhibitors to NCT may enhance pCR in locally advanced gastric or GEJ cancer. The addition of PD-1/PD-L1 inhibitors to NCT may enhance pCR in locally advanced gastric or GEJ cancer. Tislelizumab, Pembrolizumab, and Sintilimab demonstrated the most promising results, although wide credible intervals reflect substantial uncertainty for several regimens. Further comparative trials and long-term outcome data are needed to optimize NICT strategies."

Metastases • Retrospective data • Review • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II/III study (ESMO Asia 2025) - P2/3 | "S+C+AG regimen significantly improved median PFS versus AG alone, with consistent benefits across key efficacy endpoints. The safety profile is manageable. The tetrad regimen may emerge as a new frontline option for the targeted population."

Clinical • Combination therapy • Metastases • P2/3 data • Oncology • Pancreatic Cancer • Solid Tumor • FGFR

Reduced-intensity CRT plus PD-1 inhibitor for elderly ESCC: A retrospective cohort (ESMO Asia 2025) - P | "We tested a triple-optimised regimen—non-platinum monotherapy, 50.4 Gy radiotherapy and concurrent PD-1 inhibitor—to preserve efficacy and improve safety. This retrospective study enrolled consecutive patients aged ≥70 years with histologically confirmed ESCC (stage II–IV, ECOG PS 0–2) who were registered at the Cancer Center, Chongqing University Three Gorges Hospital, between January 2022 and July 2023, and were followed until August 2025.Treatment comprised 50.4 Gy/28 fractions delivered over 5.5 weeks, concurrent single-agent chemotherapy (S-1 or weekly nab-paclitaxel) and a PD-1 inhibitor (tislelizumab n=18, camrelizumab n=10, sintilimab n=6) for six cycles, followed by PD-1 inhibitor maintenance until progression or intolerance. Moderate-dose radiotherapy combined with single-agent chemotherapy and PD-1 inhibitor is active and well tolerated in elderly ESCC, including PD-L1-negative subgroups. These real-world data support prospective validation."

IO biomarker • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • PD-L1

Efficacy and safety of camrelizumab plus gemcitabine and oxaliplatin as conversion therapy for unresectable gallbladder cancer: Interim results from a single-arm, phase II prospective clinical study (ESMO Asia 2025) - P2 | "Camrelizumab combined with GEMOX shows promise as conversion therapy for unresectable GBC. However, further evaluation in a larger patient cohort is warranted."

Clinical • P2 data • Gallbladder Cancer • Oncology • Solid Tumor

Immune checkpoint inhibitors and hemophagocytic lymphohistiocytosis: Disproportionality analysis from FAERS (ESMO-IO 2025) - "Cases were grouped by PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab, sintilimab, tislelizumab, camrelizumab, retifanlimab, toripalimab) and PD-L1 inhibitors (atezolizumab, durvalumab, avelumab). Clinicians should remain vigilant for HLH—especially early fever, cytopenias, and rising ferritin—and seek prompt hematology input with diagnostic workup, which may be lifesaving. Differences may reflect pharmacodynamics, indication mix, combinations, and reporting bias; prospective, mechanism-focused studies are needed to clarify causality and guide mitigation strategies.Legal entity responsible for the study The authors."

Checkpoint inhibition • Breast Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis. (PubMed, Front Immunol) - "Compared with chemotherapy, except for ipilimumab+chemo [HR = 0.92,95%CI: (0.59-1.40)], atezolizumab+chemo [HR = 0.88, 95%CI: (0.56-1.40)], and durvalumab+chemo [HR = 0.84, 95% CI: (0.52-1.40)], durvalumab+ tremelimumab+chemo [HR = 0...Cemiplimab [HR = 0.48, 95% CI: (0.34-0.67)] showed the best OS benefit...Sugemalimab+chemo provided the best survival benefit [HR = 0.34, 95% CI: (0.24-0.48)]. For PD-L1≥50% tumors, penpulimab showed excellent OS and PFS; for PD-L1 1-49% tumors, pembrolizumab+chemo and camrelizumab+chemo achieved the best OS and PFS, respectively; for PD-L1≥1% tumors, the tislelizumab+chemo and camrelizumab+chemo showed the best OS and PFS results, while for tumors with PD-L1 <1%, both nivolumab and serplulimab+chemo provided significant survival benefit...Ipilimumab+chemo had the highest incidence of adverse events (AEs) [OR = 2.0, 95% CI:(1.5-2.7)]. https://www.crd.york.ac.uk/prospero/, identifier CRD420251027447."

Checkpoint inhibition • Clinical • IO biomarker • Journal • Retrospective data • Review • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial (clinicaltrials.gov) - P2 | N=440 | Not yet recruiting | Sponsor: Women's Hospital School Of Medicine Zhejiang University | Initiation date: Sep 2025 ➔ Jan 2026

Trial initiation date • Cervical Cancer • Oncology • Solid Tumor

Neoadjuvant Immune Checkpoint Inhibition in MSI-H/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes. (PubMed, J Gastrointest Cancer) - "Neoadjuvant immune checkpoint inhibition demonstrates high pathological and clinical response rates in dMMR/MSI-H colorectal cancer, with organ preservation achievable in selected rectal cancer patients. Neoadjuvant immunotherapy may become an alternative to surgery as the primary treatment for MSI-H/dMMR colorectal cancer if long-term quality of life is superior and toxicity and cost are competitive with standard surgical approaches. However, longer follow-up, predictive biomarkers, and randomized comparisons with upfront surgery are required before its routine clinical use."

Checkpoint inhibition • dMMR • IO biomarker • Journal • MSI-H • Review • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors. (PubMed, Ren Fail) - "The CTD group (e.g. cisplatin, capecitabine, gemcitabine) caused frequent acute kidney injury (AKI, 80%), with acute tubulointerstitial nephritis (ATIN, 32%)...The MTT group (e.g. bevacizumab, lenvatinib, sorafenib) had higher proteinuria (0.4 vs. 3.1 vs. 0.7 g/24h; p < 0.05) and TMA incidence (86%)...ICI therapy (nivolumab, camrelizumab, sintilimab) led to early AKI, mainly ATIN (80%), with glomerular IgA deposition (80%) and low serum C3 (60%)...MTT drives functional TMA, and new-onset hypertension with proteinuria should raise concern for anti-VEGF-related TMA. ICI triggers immune dysregulation with humoral disturbances, and AKI with low serum C3 can be a safety signal for clinical monitoring."

Checkpoint inhibition • Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hypertension • Nephrology • Oncology • Renal Disease

Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer. (PubMed, J Transl Med) - P1 | "A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534)."

IO biomarker • Journal • Cardiovascular • Colorectal Cancer • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia • BRAF • CD4 • CD8

Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study. (PubMed, Int J Surg) - "Compared with TACE plus lenvatinib, triple therapy with TACE, lenvatinib, and PD-1 inhibitor resulted in better PFS and OS. These findings support the consideration of this triple combination as a promising first-line treatment option for unresectable huge HCC and warrant further validation in prospective studies."

Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons. (PubMed, Adv Ther) - P3 | "Tislelizumab appears comparable to existing anti-PD-1 therapies (nivolumab, pembrolizumab, camrelizumab, and sintilimab) in OS, PFS, and TRAEs of grade ≥ 3 for patients receiving second-line treatment for ESCC with a potentially more favorable TRAE grade ≥ 3 profile than camrelizumab that requires confirmation."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. (PubMed, Lancet Oncol) - P3 | "At final analysis, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement compared with sorafenib, with manageable safety. The extended follow-up further confirmed the benefit-to-risk profile of camrelizumab plus rivoceranib, supporting the combination as a new first-line treatment option for unresectable hepatocellular carcinoma."

Clinical • Journal • P3 data • Cardiovascular • Hepatocellular Cancer • Hypertension • Oncology • Respiratory Diseases • Solid Tumor

Comparative short-term outcomes of peri-operative immunotherapy and targeted therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. (PubMed, Eur J Surg Oncol) - "The absence of direct head-to-head trials prompted the use of a network meta-analysis to compare the short-term efficacy of treatment regimens for gastric and gastroesophageal junction adenocarcinoma. Our findings suggest that immunotherapies or targeted therapies, when combined with chemotherapy, are likely to yield superior pathological responses compared to chemotherapy alone. However, these conclusions are based on intermediate endpoints and on limited study quality. Therefore, definitive ranking of these regimens requires validation through large, well-designed, direct randomized trials focused on long-term survival outcomes."

Clinical • Journal • Retrospective data • Review • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

HLB liver cancer combo beats Nexavar in phase 3 with nearly 2-year survival (Korea Biomedical Review) - "Landmark analyzes showed 77 percent of patients on the combo alive at 12 months versus 61 percent on sorafenib, 49 percent versus 33 percent at 24 months and 38 percent versus 25 percent at 36 months, despite more patients in the sorafenib arm receiving subsequent systemic therapy, including immunotherapy and targeted drugs. Median progression-free survival was 5.6 months with camrelizumab plus riboceranib and 3.7 months with sorafenib, with a hazard ratio of 0.54."

P3 data • Hepatocellular Cancer

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Henan Cancer Hospital | Trial completion date: Nov 2025 ➔ May 2026 | Trial primary completion date: Nov 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer (clinicaltrials.gov) - P=N/A | N=1300 | Not yet recruiting | Sponsor: Qi Zhou

Monotherapy • New trial • Cervical Cancer • Oncology • Solid Tumor

Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma. (PubMed, Cell Rep Med) - P2 | "Exploratory analysis indicates that responders show significantly higher tumor PD-L1 expression than non-responders do, with median tumor proportion scores of 8% and 2%, respectively. The study is registered at ClinicalTrials.gov (NCT05236699)."

IO biomarker • Journal • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2 • PD-L1